|
INTRAUTERINE GROWTH RESTRICTION |
Cochrane Database Syst Rev. 2003;(1):CD000137.
Maternal oxygen administration for suspected impaired fetal growth.
Say L, G?mezoglu AM, Hofmeyr GJ.
Department of Reproductive Health and Research, World Health Organization,
20 Avenue Appia, Geneva 27, Switzerland. sayl@who. Int
Background:
Fetal hypoxaemia is often a feature of fetal growth impairment.
It has been suggested that perinatal outcome after suspected impaired fetal
growth might be improved by giving mothers continuous oxygen until delivery.
Objectives:
The objective was to assess the effects of maternal oxygen
therapy in suspected impaired fetal growth on fetal growth and perinatal
outcome.
Search Strategy:
We searched the Cochrane Pregnancy and Childbirth
Group trials register (November 2002).
Selection Criteria:
Acceptably
controlled trials comparing maternal oxygen therapy with no oxygen therapy
in suspected impaired fetal growth. DATA COLLECTION AND ANALYSIS:
Eligibility and trial quality was assessed. Main Results:
Three studies
involving 94 women were included. Oxygenation compared with no oxygenation
was associated with a lower perinatal mortality rate (relative risk: 0.50,
95% confidence interval 0.32 to 0.81). However, higher gestational age in
the oxygenation groups may have accounted for the difference in mortality
rates. REVIEWER'S Conclusions:
There is not enough evidence to evaluate the
benefits and risks of maternal oxygen therapy for suspected impaired fetal
growth. Further trials of maternal hyperoxygenation seem warranted.
| 
